The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of the Lung Immune Prognostic Index with outcome in patients with metastatic urothelial cancer treated with immune checkpoint inhibitor.
 
Parent Pauline
Travel, Accommodations, Expenses - Pfizer
 
Edouard Auclin
Honoraria - Genzyme
Travel, Accommodations, Expenses - Mundipharma
 
Laura Mezquita
Consulting or Advisory Role - Roche; Roche; Takeda
Speakers' Bureau - Bristol-Myers Squibb; Roche; Tecnofarma
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche; Roche
 
Nieves M. Chanza
No Relationships to Disclose
 
Clement Dumont
Travel, Accommodations, Expenses - Ipsen
 
Alejo Rodriguez-Vida
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen Oncology; MSD; Novartis; Pfizer; Roche; Sanofi
Research Funding - MSD (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Janssen Oncology; Pfizer; Roche
 
Rebeca Lozano
Consulting or Advisory Role - Sanofi/Aventis
Speakers' Bureau - Janssen-Cilag; Roche
Research Funding - Bayer (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Janssen-Cilag; Roche
 
Beatriz Vera
No Relationships to Disclose
 
Raffaele Ratta
Consulting or Advisory Role - Astellas Pharma; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer
 
Giulia Baciarello
No Relationships to Disclose
 
Emeline Colomba
No Relationships to Disclose
 
Alina Fuerea
No Relationships to Disclose
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Biogen (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Inivata (Inst); Ipsen (Inst); Lilly (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Onxeo (Inst); Pfizer (Inst); PharmaMar (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst); Tiziana Therapeutics (Inst)
 
Yohann Loriot
Honoraria - Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Janssen; Janssen (Inst); MSD Oncology; MSD Oncology (Inst); Roche; Seagen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); CureVac (Inst); Exelixis (Inst); Incyte (Inst); Janssen Oncology (Inst); Medivation (Inst); MSD Oncology (Inst); Nektar (Inst); Oncogenex (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Pernelle Lavaud
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Janssen; Mundipharma Research; Pfizer